Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Down 64.1% in July

Posted by Brenda Bartman on Aug 16th, 2026

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 93,141 shares, a decrease of 64.1% from the July 15th total of 259,720 shares. Based on an average daily volume of 88,009 shares, the short-interest ratio is presently 1.1 days. Currently, 0.1% of the shares of the company are sold short.

Indaptus Therapeutics Price Performance

NASDAQ INDP traded up $0.01 during trading hours on Friday, reaching $1.07. The company’s stock had a trading volume of 130,848 shares, compared to its average volume of 114,071. The firm has a market capitalization of $121.17 million, a price-to-earnings ratio of -0.17 and a beta of 1.18. The company’s 50-day moving average is $2.51 and its two-hundred day moving average is $2.21. Indaptus Therapeutics has a 1-year low of $0.92 and a 1-year high of $8.57.

Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on INDP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics has a consensus rating of “Sell”.

Check Out Our Latest Analysis on Indaptus Therapeutics

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.